A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

Eduardo Tolosa, Irene Litvan, Günter U. Höglinger, David Burn, Andrew Lees, María V. Andrés, Belén Gómez-Carrillo, Teresa León, Teodoro Del Ser, J. C. Gómez, B. Tijero, K. Berganzo, J. García de Yebenes, J. L. Lopez Sendón, G. Garcia, E. Tolosa, M. T. Buongiorno, N. Bargalló, J. A. Burguera, I. MartinezJ. Ruiz-Martínez, I. Narrativel, F. Vivancos, I. Ybot, M. Aguilar, P. Quilez, M. Boada, A. Lafuente, I. Hernandez, J. J. López-Lozano, M. Mata, A. Kupsch, A. Lipp, G. Ebersbach, T. Schmidt, K. Hahn, G. Höglinger, M. Höllerhage, W. H. Oertel, G. Respondek, M. Stamelou, H. Reichmann, M. Wolz, C. Schneider, L. Klingelhöfer, D. Berg, W. Maetzler, K. K. Srulijes, A. Ludolph, J. Kassubek, M. Steiger, K. Tyler, L. Morris, A. Lees, H. Ling, R. Hauser, T. McClain, D. Truong, S. Jenkins, I. Litvan, D. Houghton, J. Ferrara, Y. Bordelon, A. Gratiano, L. Golbe, M. Mark, R. Uitti, J. Ven Gerpen

Research output: Contribution to journalArticlepeer-review

176 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy'. Together they form a unique fingerprint.

Medicine & Life Sciences